|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3445357B1
(en)
|
2016-04-22 |
2021-05-26 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
CA3018429A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
MX2019007646A
(es)
*
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
AU2018219292B2
(en)
*
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019121562A1
(en)
|
2017-12-18 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
|
|
EP3746426A4
(en)
|
2018-01-29 |
2021-12-29 |
Dana Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
WO2019160915A1
(en)
|
2018-02-14 |
2019-08-22 |
Dana-Farber Cancer Institute, Inc. |
Irak degraders and uses thereof
|
|
US20210077469A1
(en)
*
|
2018-02-20 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pharmaceutical combinations of egfr inhibitors and methods of use thereof
|
|
WO2019183523A1
(en)
*
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CN108610333B
(zh)
*
|
2018-06-08 |
2020-04-03 |
绍兴文理学院 |
诱导MDM2自我降解E3泛素连接酶二聚体酰胺类小分子PROTACs
|
|
CN108610332B
(zh)
*
|
2018-06-08 |
2020-04-03 |
绍兴文理学院 |
诱导MDM2自我降解E3泛素连接酶二聚体酯类小分子PROTACs
|
|
WO2019241231A1
(en)
*
|
2018-06-11 |
2019-12-19 |
Abhishek Sharma |
Antiestrogen compounds
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
WO2020069125A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Dana-Farber Cancer Institute, Inc. |
Degraders of hepatitis c virus ns3/4a protein
|
|
JP2022507267A
(ja)
|
2018-11-13 |
2022-01-18 |
バイオセリックス， インコーポレイテッド |
置換イソインドリノン
|
|
EP3932922A4
(en)
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
WO2020191369A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
|
CN120172958A
(zh)
|
2019-04-12 |
2025-06-20 |
C4医药公司 |
Ikaros和aiolos的三环降解物
|
|
CN110204532B
(zh)
*
|
2019-05-15 |
2022-03-08 |
浙江工业大学 |
一种靶向egfr蛋白降解的化合物及其制备方法和应用
|
|
US12377080B2
(en)
|
2019-06-21 |
2025-08-05 |
Dana-Farber Cancer Institute, Inc. |
Allosteric EGFR inhibitors and methods of use thereof
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
WO2021023233A1
(zh)
*
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
CN115397821B
(zh)
|
2019-10-17 |
2024-09-03 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
KR20220114615A
(ko)
*
|
2019-12-16 |
2022-08-17 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Egfr 키나제의 분해를 억제 및 유도하는 화합물
|
|
CA3165168A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
BR112022011827A2
(pt)
|
2019-12-20 |
2022-08-30 |
C4 Therapeutics Inc |
Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
|
|
WO2021152113A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Bayer Aktiengesellschaft |
Substituted 2,3-benzodiazepines derivatives
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN111592535B
(zh)
*
|
2020-06-22 |
2021-07-20 |
通化师范学院 |
一种抗egfr突变的抑制剂eai045的制备方法
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
CN114057770B
(zh)
*
|
2020-08-06 |
2023-05-02 |
成都先导药物开发股份有限公司 |
靶向egfr蛋白降解的双功能化合物
|
|
JP7834721B2
(ja)
|
2020-08-28 |
2026-03-24 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
US20230322723A1
(en)
*
|
2020-09-11 |
2023-10-12 |
J2H Biotech Inc. |
Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
CN112608302B
(zh)
*
|
2020-12-28 |
2022-05-24 |
郑州大学第一附属医院 |
低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
|
|
US20240165243A1
(en)
|
2021-02-10 |
2024-05-23 |
Beigene Switzerland Gmbh |
Egfr degraders and methods of use
|
|
CN113004251B
(zh)
*
|
2021-03-05 |
2022-09-27 |
郑州大学第一附属医院 |
含2-硝基咪唑的喹唑啉类衍生物及其应用
|
|
KR20240016250A
(ko)
*
|
2021-04-02 |
2024-02-06 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암 치료를 위한 병용요법
|
|
CN117279910A
(zh)
|
2021-04-16 |
2023-12-22 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
US11981678B2
(en)
|
2021-04-29 |
2024-05-14 |
Northwestern University |
Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein
|
|
US12042543B2
(en)
|
2021-04-30 |
2024-07-23 |
Northwestern University |
Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115109055B
(zh)
*
|
2022-05-26 |
2023-11-28 |
北京康辰药业股份有限公司 |
一种用于egfr降解的双功能化合物及其应用
|
|
CN115160311B
(zh)
*
|
2022-05-26 |
2024-03-15 |
北京康辰药业股份有限公司 |
一种用于egfr降解的双功能化合物及其应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
CN115286643B
(zh)
*
|
2022-09-02 |
2023-09-01 |
南京大学 |
蛋白质靶向降解化合物及其制备方法和应用
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
WO2024086132A1
(en)
*
|
2022-10-17 |
2024-04-25 |
Ohio University |
Protacs targeting viral enzymes for precise treatment of covid-19
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
CN119317636A
(zh)
*
|
2023-03-07 |
2025-01-14 |
艾博生物科技(上海)有限公司 |
编码活化EGFR突变肽的免疫调节治疗性mRNA组合物
|
|
AU2024281173A1
(en)
|
2023-05-31 |
2025-12-04 |
Beone Medicines I Gmbh |
Compounds for the degradation of egfr kinase
|
|
CN121368481A
(zh)
*
|
2023-06-29 |
2026-01-20 |
丹娜-法伯癌症研究院 |
用于降解dna甲基转移酶1 (dnmt1)的蛋白水解靶向嵌合体(protacs)的合成和体外表征
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025137613A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Ganymede Oncology, Inc. |
Cycloalkylene nrf2 protein degraders
|
|
WO2025235298A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
|